We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision.
- Authors
Mackintosh, John A.; Keir, Gregory; Troy, Lauren K.; Holland, Anne E.; Grainge, Christopher; Chambers, Daniel C.; Sandford, Debra; Jo, Helen E.; Glaspole, Ian; Wilsher, Margaret; Goh, Nicole S. L.; Reynolds, Paul N.; Chapman, Sally; Mutsaers, Steven E.; de Boer, Sally; Webster, Susanne; Moodley, Yuben; Corte, Tamera J.
- Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive disease leading to significant morbidity and mortality. In 2017 the Thoracic Society of Australia and New Zealand (TSANZ) and Lung Foundation Australia (LFA) published a position statement on the treatment of IPF. Since that time, subsidized anti‐fibrotic therapy in the form of pirfenidone and nintedanib is now available in both Australia and New Zealand. More recently, evidence has been published in support of nintedanib for non‐IPF progressive pulmonary fibrosis (PPF). Additionally, there have been numerous publications relating to the non‐pharmacologic management of IPF and PPF. This 2023 update to the position statement for treatment of IPF summarizes developments since 2017 and reaffirms the importance of a multi‐faceted approach to the management of IPF and progressive pulmonary fibrosis.
- Subjects
NEW Zealand; AUSTRALIA; PULMONARY fibrosis; INTERSTITIAL lung diseases; DISEASE progression; IDIOPATHIC pulmonary fibrosis
- Publication
Respirology, 2024, Vol 29, Issue 2, p105
- ISSN
1323-7799
- Publication type
Article
- DOI
10.1111/resp.14656